5-Hydroxymethyl-oxazolidin-2-one antibacterials

Bibliography

• Antimicrobial resistance prevention initiative: proceedings of an expert panel of resistance. Am J Infect Control 2006;34(5 Suppl):A1-S79
   PubMed Web of Science ®Google Scholar
• Fauci AS, Touchette NA, Folkers GK. Emerging infectious diseases: a 10-Year perspective from the National institute of allergy and infectious diseases. Emerg Infect Dis 2005;11(4):519-25
   PubMed Web of Science ®Google Scholar
• Wookey A, Turner PJ, Greenhalgh JM, et al. AZD25663, a novel oxazolidinone: definition of antibacterial spectrum, assessment of antibacterial potential and the impact of miscellaneous factors on activity in vitro. Clin Microbiol Infect 2004;10:247-54
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004;39(3):309-17
   PubMed Web of Science ®Google Scholar
• National Nosocomial Infections Surveillance System. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992 through June 2004. Am J Infect Control 2004;32:470-85
   PubMed Web of Science ®Google Scholar
• Poce G, Zappia G, Porretta GC. New oxazolidinone derivatives as antibacterial agents with improved activity. Expert Opin Ther Patents 2008;18(2):97-121
   Web of Science ®Google Scholar
• Prasad JVNV. New oxazolidinones. Curr Opin Microbiol 2007;10:454-60
   PubMedGoogle Scholar
• Gravestock MB. Recent developments in the discovery of novel oxazolidinone antibacterials. Curr Opin Drug Discov Dev 2005;8(4):469-77
   PubMedGoogle Scholar
• Lundstrom TS, Sobel JD. Antibiotics for Gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid and daptomycin. Infect Dis Clin N Am 2004;18:651-68
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23(2):113-9
   PubMed Web of Science ®Google Scholar
• Hutchinson DK. Oxazolidinone antibacterial agents: a critical review. Curr Top Med Chem 2003;3:1021-42
   PubMed Web of Science ®Google Scholar
• Barbachyn MR, Ford CW. Oxazolidinone structure-activity relationships leading to linezolid. Angew Chem Int Ed 2003;42:2010-23
   PubMed Web of Science ®Google Scholar
• Ippolito JA, Kanyo ZF, Wang D, et al. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J Med Chem 2008;51:3353-6
   PubMed Web of Science ®Google Scholar
• Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001;358:207-8
   PubMed Web of Science ®Google Scholar
• Gonzales RD, Schreckenberger PC, Graham MB, et al. Infection due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001;357(9263):1179
   PubMed Web of Science ®Google Scholar
• Johnson AP, Tysall L, Stockdale MW, et al. Emerging linezolid-resistant Enterococcus faecalis and Enterococcus faecium isolated from two Austrian patients in the same intensive care unit. Eur J Clin Microbiol Infect Dis 2002;21:751-4
   PubMed Web of Science ®Google Scholar
• Rahim S, Pillai K, Gold HS, et al. Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid. Clin Infect Dis 2003;36:e146-148
   PubMed Web of Science ®Google Scholar
• Centers for disease control and prevention. Staphylococcus aureus resistant to vancomycin – United States. Morb Mortal Rep 2002;51(26):565-7
   Google Scholar
• Centers for disease control and prevention. Public health dispatch: vancomycin-resistant Staphylococcus aureus – Pennsylvania. Morb Mortal Rep 2002;51(40):902-3
   Google Scholar
• Centers for disease control and prevention. Vancomycin-resistant Staphylococcus aureus – New York. Morb Mortal Rep 2004;53(15):322-3
   Google Scholar
• Patel R. Clinical impact of vancomycin-resistant enterococci. J Antimicrob Chemother 2003;51:13-21
   Google Scholar
• Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 1997;41:24-9
   PubMedGoogle Scholar
• Hamilton-Miller JMT. Dual-action antibiotic hybrids. J Antimicrob Agents Chemother 1994;33:197-200
   Google Scholar
• Hubschwerlen C, Specklin JL, Sigwalt C, et al. Design, synthesis and biological evaluation of oxazolidinone-quinolone hybrids. Bioorg Med Chem 2003;11:2313-9
   PubMed Web of Science ®Google Scholar
• Hubschwerlen C, Specklin JL, Baeschlin DK, et al. Structure-activity relationship in the oxazolidinone-quinolone hybrid series: influence of the central spacer on the antibacterial activity and the mode of action. Bioorg Med Chem Lett 2003;13:4229-33
   PubMed Web of Science ®Google Scholar
• Morphochem AG. Dual action antibiotics. WO03032962; 2003
   Google Scholar
• Morphochem AG. Dual actions antibiotics comprising a oxazolidinones and a quinolone or naphthyridinone moiety. WO03031443; 2003
   Google Scholar
• Morphochem AG. Use of oxazolidinone-quinolone hybrid antibiotics for the treatment of anthrax and other infections. WO2004096221; 2004
   Google Scholar
• Morphochem AG. Intermediate products for producing oxazolidinones-quinolone hybrids. WO2005023801; 2005
   Google Scholar
• Morphochem AG. Oxazolidinone-quinolone hybrid antibiotics. WO2005058888; 2005
   Google Scholar
• Gordeev MF, Hackbarth C, Barbachyn MR, et al. Novel oxazolidinone–quinolone hybrid antimicrobials. Bioorg Med Chem Lett 2003;13:4213
   PubMed Web of Science ®Google Scholar
• Bozdogan B, Appelbaum PC. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004;23(2):113-9
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Update on linezolid: the first oxazolidinone antibiotic. Expert Opin Pharmacother 2005;6(13):2315-25
   PubMed Web of Science ®Google Scholar
• Renslo AR, Luehr GW, Gordeev MF. Recent developments in the identification of novel oxazolidinone antibacterial agents. Bioorg Med Chem 2006;14:4227-40
   PubMed Web of Science ®Google Scholar
• Ferry T, Ponceau B, Simon M, et al. Possibly linezolid-induced peripheral and central neurotoxicity: report of four cases. Infection 2005;33:151-4
   PubMed Web of Science ®Google Scholar
• Rucker JC, Hamilton SR, Bardenstein D, et al. Linezolid-associated toxic optic neuropathy. Neurology 2006;66(4):595-8
   PubMed Web of Science ®Google Scholar
• Young LS. Hematologic effects of linezolid versus vancomycin. Clin Infect Dis 2004;38:1065-6
   PubMed Web of Science ®Google Scholar
• Morales-Molina JA, Antonio JMDE, Marín-Casino M, Grau S. Linezolid-associated serotonin syndrome: what can we learn from cases reported so far. J Antimicrob Chemother 2005;56:1176-8
   PubMed Web of Science ®Google Scholar
• Reck F, Zhou F, Girardot M, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499-506
   PubMed Web of Science ®Google Scholar
• Atterson PR, Takacs K, Schlosser MJ. Absence of pressor response to oral tyramine in conscious telemeterized rats treated with novel oxazolidinone TR-701: comparison to linezolid [abstract F1-2067]. ICAAC 2008:p312
   Google Scholar
• Shaw KJ, Poppe S, Schaadt R, et al. In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother 2008;52(12):4442-7
   PubMed Web of Science ®Google Scholar